$

SIBE

$

Über uns

$

Mission/Leitbild

$

Geschichte

$

Team

$

Forschungsschwerpunkte

$

Publikationen

$

Presse

$

Stellen bei der SIBE

$

Standorte

$

Rechtliches

$

Impressum

$

Datenschutzerklärung

$

Business Performance

$

Business Projects

$

Innovation Projects

$

Scientififc Projects

$

Projektbeispiele

$

Personal

$

Rekrutierung

$

Mitarbeiterbindung

$

Employer Branding

$

Persönlichkeitsentwicklung

$

Partner

$

School

$

Programme

$

M.Sc. International Management – SIBE-Management-Master

$

German-US-Dual-Degree (M.Sc./MBA)

$

M.Sc. in Digital Leadership

$

Diploma of Perfomance and Leadership

$

LL.M. in International Business Law

$

Doctor of Business Administration (DBA)

$

Erfahrungsberichte

$

Lehre

$

Mitglieder

$

Systemakkreditierung

$

Qualität

$

Partnerhochschulen

$

Studierende & Alumni

$

Mentoring

$

Für Gründer

$

Benefits & Netzwerke

$

Empfehlungsprämien

$

E-Campus

$

Stellenangebote

$

Projektbeispiele

$

Downloads

$

FAQ

Using disruption to secure universal health coverage

2. November 2021
Redaktion SIBE

Counterfeit drugs whose patents have expired are already having a massive impact on healthcare systems around the world. The so-called generics and their biotechnological mirror image, the biosimilars, are conquering more and more clinics and households, also in Europe. Especially the low price makes these drugs so popular from the point of view of the health insurance companies, for the patients. But will copying off-patent drugs still prove lucrative for generics and biosimilar manufacturers when technological developments have rapidly accelerated the innovation cycles of original manufacturers in the future? Or will classic “one fits all” drugs still be in demand at all in a future where personalized medicine prevails?

These and other exciting questions are addressed in the latest scientific study by the School of International Business and Entrepreneurship (SIBE), in cooperation with Pro Generika e. V.. The publication “The Future of the European Generics and Biosimilars Industry 2030plus” provides scientific insights into the perceptions of more than 60 experts on the future of the industry based on a real-time Delphi survey. It shows which future developments the experts consider likely, influential and desirable. On this basis, four exciting and plausible future scenarios for the generics and biosimilars industry, as well as related industries, are depicted with the help of the established scenario technique. The focus here is, for example, on the relevance of new technologies, such as 3D printing for drug production, or the disruptive power of large technology companies for the industry.

Beyond the scientifically based insights of the Delphi-based scenarios, the reading outlines options for action for companies in the pharmaceutical industry, particularly in the generics and biosimilars sectors. In these, a wide variety of opportunities for the organizations are taken up, which can already be recognized today. The scientific study is rounded off by interviews with outstanding personalities from the industry. For example, thought leaders such as Biontech investor Dr. Thomas Strüngmann and CureVac founder Dr. Ingmar Hoerr will present their visions of the future of the pharmaceutical industry and the disruptive developments foreseeable in this field.

Immerse yourself now in the different scenario worlds that depict the future of all our health and read the study “The Future of the European Generics and Biosimilars Industry 2030plus”.

Are you interested in other SIBE projects in the pharmaceutical sector? Learn more about the experiences of our partners in the industry now.

more posts

All the Best, SMM186

The two-year course is over, the SMM185 course has successfully completed the Master in "International Management" at SIBE. The former students are now devoting themselves to new challenges. We would like to congratulate all graduates once again and look forward to...

read more